Partial Epilepsy
📧 Sign up to get email alerts when something new happens for Partial Epilepsy.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Lacosamide UCB (lacosamide) — UCB Pharma S.A.
EMA authorises lacosamide (Lacosamide UCB) for partial epilepsies in EU.
-
EMA approval · 2026-07-22EMA Authorised: Kigabeq (vigabatrin) — ORPHELIA Pharma
EMA has authorised Kigabeq (vigabatrin) for infantile spasms and partial epilepsies, with ORPHELIA Pharma as the marketing authorization hol…
-
EMA approval · 2026-07-10EMA Authorised: Fycompa (perampanel) — Eisai GmbH
The EMA authorises Fycompa (perampanel) for partial epilepsies in Europe, with Eisai GmbH as the marketing authorization holder.
-
EMA approval · 2026-02-19EMA Authorised: Kigabeq (vigabatrin) — ORPHELIA Pharma
The EMA has authorised Kigabeq (vigabatrin) by ORPHELIA Pharma for infantile spasms and partial epilepsies.
-
EMA approval · 2025-05-23EMA Authorised: Lacosamide UCB (lacosamide) — UCB Pharma S.A.
The European Medicines Agency authorised a lacosamide product (Lacosamide UCB) from UCB Pharma S.A., for partial epilepsy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.